Hints and tips:
Related Special Reports
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...Now, the US drugmaker is behind the pharmaceutical product with the record for sales in a single year....
...“Africa is a key market for Sputnik V,” said the Russian Direct Investment Fund, a Kremlin-run wealth fund overseeing Sputnik V’s foreign sales....
...The best, such as Denmark, are on a par with England at the same stage of rollout....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...“We can definitely say that the transparency from Oxford and AstraZeneca has not been on a par with what we have seen from the others,” said Rasmus Bech Hansen, chief executive of Airfinity, a London-based...
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...If there is a sense from this earnings season that confidence in a V-shaped recovery for profits is misplaced, then the impact will probably be hardest on companies with weak balance sheets, and on those...
...Beyond these three biotechs, Crispr could end up transforming the entire pharmaceutical industry....
...Their concentrated ownership of industries such as airlines and pharmaceuticals may push up travel and drug prices, some academics argue....
...She worked as a janitorial supervisor at C&W client Lonza, a Swiss pharmaceuticals group, which has a production facility in Portsmouth, New Hampshire....
...Those bonds had previously traded as high as 101 cents on the dollar, but were ultimately called at par. Qualcomm also sought to buy some of its debt back at par. The cases are often more extreme....
...He places human embryonic and pluripotent stem cells — that have the potential to grow into nearly every cell of the body — in tiny ‘U’ or ‘V’ shaped dishes in the lab to grow them into different types of...
...Pharmaceutical groups, which might see similar benefits from quantum technology in the long term, are still on the sidelines....
...Watson Pharmaceuticals and Par Pharmaceutical have previously been prevented from working on a generic film alternative, but Indivior said the latest ruling means they “are now able to pursue their respective...
...When Amazon bought a big stake in drugstore.com in 1999, Jeff Bezos thought he could do for pharmaceuticals what he had done for books, stealing market share from bricks-and-mortar pharmacies and bringing...
...Reddy’s Laboratories, Inc.; Emcure Pharmaceuticals, Ltd.; Glenmark Pharmaceuticals, Inc.; Lannett Company, Inc.; Par Pharmaceutical Companies, Inc.; Sandoz, Inc.; Sun Pharmaceutical Industries,Inc.; and...
...Thanks to a series of court rulings since the mid-2000s, such as eBay v MercExchange in 2007, Mayo Collaborative Services v Prometheus Laboratories in 2012 and Alice Corp v CLS Bank in 2014, and the subsequent...
...the neuroscience business should not “shock investors but is likely to raise a debate over possible use of proceeds should any cash be generated and management of any earnings dilution [ie deleveraging v...
...Mr Campanelli previously served as chief executive of Par Pharmaceutical and joined Endo after the company bought Par in 2015....
...The company also helped to assuage investor fears over the margins of its newer growth businesses, by disclosing a commercial cloud gross margin of 48 per cent — on par with the previous quarter....
...Dechra Pharmaceuticals, the veterinary medicines maker, was down 3.7 per cent to £11.34 after Jefferies restarted coverage with “hold” advice....
...Dealmakers have struck $460bn in M&A transactions in healthcare since the year began, including Valeant’s $15.8bn deal for Salix, as well as Endo’s purchase of Par Pharmaceutical from TPG Capital and Mallinckrodt...
...Why, then, is the market so tepid on Endo’s $8bn cash and stock purchase of Par, a generics company? After Monday’s announcement, Endo’s shares fell 5 per cent....
International Edition